Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Current Pharmaceutical Design
|
February 7, 2003
Emerging beta-amyloid therapies for the treatment of Alzheimer's disease
Kelly A Conway, Ellen W Baxter, Kevin M Felsenstein, et al.
Current Alzheimer Research
|
July 14, 2007
A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta
George J Yohrling, Kevin M Felsenstein, Kelly A Conway, et al.
Journal of Molecular Neuroscience : MN
|
May 6, 2004
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease
Jean-Christophe Rochet, Tiago Fleming Outeiro, Kelly A Conway, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 21, 2022
Monoamine oxidase binding not expected to significantly affect [<sup>18</sup>F]flortaucipir PET interpretation
Justin P Wright, Jason R Goodman, Yin-Guo Lin, et al.
Bioorganic & Medicinal Chemistry
|
September 6, 2002
Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation
Michael H Parker, Robert Chen, Kelly A Conway, et al.
Journal of Biomolecular Screening
|
July 12, 2003
Virus-based expression systems facilitate rapid target in vivo functionality validation and high-throughput screening
Andrew L Darrow, Kelly A Conway, Anil H Vaidya, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2010
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads
Yifang Huang, Eric D Strobel, Chih Y Ho, et al.
Journal of Medicinal Chemistry
|
August 10, 2007
2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead
Ellen W Baxter, Kelly A Conway, Ludo Kennis, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Current Pharmaceutical Design
|
February 7, 2003
Emerging beta-amyloid therapies for the treatment of Alzheimer's disease
Kelly A Conway, Ellen W Baxter, Kevin M Felsenstein, et al.
Current Alzheimer Research
|
July 14, 2007
A comparative analysis of brain and plasma Abeta levels in eight common non-transgenic mouse strains: validation of a specific immunoassay for total rodent Abeta
George J Yohrling, Kevin M Felsenstein, Kelly A Conway, et al.
Journal of Molecular Neuroscience : MN
|
May 6, 2004
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease
Jean-Christophe Rochet, Tiago Fleming Outeiro, Kelly A Conway, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
May 21, 2022
Monoamine oxidase binding not expected to significantly affect [<sup>18</sup>F]flortaucipir PET interpretation
Justin P Wright, Jason R Goodman, Yin-Guo Lin, et al.
Bioorganic & Medicinal Chemistry
|
September 6, 2002
Synthesis of (-)-5,8-dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: an inhibitor of beta-amyloid(1-42) aggregation
Michael H Parker, Robert Chen, Kelly A Conway, et al.
Journal of Biomolecular Screening
|
July 12, 2003
Virus-based expression systems facilitate rapid target in vivo functionality validation and high-throughput screening
Andrew L Darrow, Kelly A Conway, Anil H Vaidya, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 20, 2010
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads
Yifang Huang, Eric D Strobel, Chih Y Ho, et al.
Journal of Medicinal Chemistry
|
August 10, 2007
2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead
Ellen W Baxter, Kelly A Conway, Ludo Kennis, et al.
Page
of 1